ABBV · 8-K · 20260622PR076067

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-06-22 · Importance 71 · Surprise 60 · In source text

AbbVie agreed to acquire all outstanding shares of Apogee Therapeutics for $135.11 per share in cash, representing an approximately $10.9 billion total equity value. The transaction adds Apogee’s clinical-stage immunology pipeline, including zumilokibart (APG777) for atopic dermatitis and APG273 for asthma. The deal is expected to close in the third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2032.

Key facts

• AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. source
• The transaction values Apogee at a total equity value of approximately $10.9 billion. source
• This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals. source
• Fairmount Funds Management LLC and Venrock Associates have entered into voting agreements in support of the transaction. source
• Apogee intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. source
• The boards of directors of both companies have unanimously approved the transaction. source
• The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie’s clinical presence in the respiratory space. source
• A meeting of the stockholders of Apogee will be announced as promptly as practicable to seek Apogee stockholder approval in connection with the proposed transaction. source

Impact estimates